padrão ((~JJ)_NN_IN)_(JJ_NN)_(~NN)

#Sem nome próprio
1. Java: (?:(?:[\\w-/]*_(?:[^J].?.?\\s|J[^J].?\\s)|^)[\\w-/]*_NN[S]?\\s[\\w-/]*_IN)(\\s[\\w-/]*_JJ[RS]?\\s[\\w-/]*_NN[S]?)(?:\\s[\\w-/]*_(?:[^N]..?|N[^N].?)|\\s\\._|\\s,_|\\s:_|\\s;_|$)
2. Perl: (?:(?:[\w-/]*_(?:[^J].?.?\s|J[^J].?\s)|^)[\w-/]*_NN[S]?\s[\w-/]*_IN)(\s[\w-/]*_JJ[RS]?\s[\w-/]*_NN[S]?)(?:\s[\w-/]*_(?:[^N]..?|N[^N].?)|\s\._|\s,_|\s:_|\s;_|$)
	// \w  Casa letras, dígitos, ou '_'.
	// 1 e 2 são equivalentes
	// Regra termina com ponto final, vírgula, ponto e vírgula, dois pontos ou $.
	// Teve termo com nome próprio (NNP), falso positivo

Sentences Examples:

During_IN 426_CD patient-years_NNS of_IN follow-up_JJ for_IN patients_NNS with_IN standard_JJ criteria_NNS ,_, 3.3_CD acute_JJ chest_NN syndromes_NNS ,_, 1.3_CD cerebrovascular_JJ events_NNS ,_, and_CC 1.1_CD osteonecrosis_NNS per_IN 100_CD patient-years_NNS were_VBD observed_VBN ._. 

In_IN 72_CD patients_NNS evaluated_VBN by_IN transcranial_JJ Doppler_NNP studies_NNS -LRB-_-LRB- TCD_NNP -RRB-_-RRB- ,_, 34_CD patients_NNS were_VBD at_IN risk_NN of_IN primary_JJ stroke_NN and_CC only_RB 1_CD had_VBD a_DT cerebrovascular_JJ event_NN after_IN a_DT follow-up_JJ of_IN 96_CD patient-years_NNS ._. 

Despite_IN a_DT sustained_JJ increase_NN in_IN HbF_NNP level_NN and_CC an_DT increase_NN in_IN hydroxyurea_NN doses_NNS to_TO 30_CD mg\/kg_NN per_IN day_NN ,_, a_DT girl_NN aged_VBN 13_CD months_NNS at_IN inclusion_NN with_IN previous_JJ history_NN of_IN splenic_JJ sequestration_NN ,_, was_VBD hospitalized_VBN 20_CD times_NNS during_IN these_DT 2_CD years_NNS of_IN HU_NNP therapy_NN and_CC continued_VBD to_TO present_VB multiple_JJ vaso-occlusive_JJ crises_NNS and_CC dactylitis_NNS during_IN the_DT first_JJ year_NN of_IN HU_NNP ._. 

She_PRP died_VBD during_IN the_DT second_JJ year_NN of_IN therapy_NN from_IN acute_JJ severe_JJ anemia_NN during_IN an_DT episode_NN of_IN splenic_JJ sequestration_NN ._. 

There_EX were_VBD 8_CD patients_NNS followed_VBD for_IN a_DT median_NN of_IN 6_CD years_NNS -LRB-_-LRB- range_NN ,_, 3-9_CD years_NNS -RRB-_-RRB- ,_, with_IN 44_CD cumulative_JJ patient-years_NNS of_IN follow-up_JJ ,_, at_IN risk_NN of_IN secondary_JJ stroke_NN ._. 

Recurrent_JJ stroke_NN occurred_VBD in_IN one_CD patient_NN after_IN 6_CD years_NNS of_IN follow-up_JJ despite_IN evidence_NN of_IN good_JJ compliance_NN with_IN therapy_NN as_IN assessed_VBN by_IN hematologic_JJ response_NN to_TO HU_NNP ._. 

As_IN a_DT whole_NN ,_, 34_CD patients_NNS were_VBD considered_VBN at_IN risk_NN of_IN primary_JJ stroke_NN on_IN the_DT basis_NN of_IN abnormal_JJ TCD_NNP ,_, and_CC 7_CD of_IN the_DT 21_CD explored_VBN by_IN MRI\/MRA_NNP had_VBD moderate\/severe_JJ arterial_JJ stenosis_NN ._. 

In_IN transfused_VBN patients_NNS ,_, the_DT prevalence_NN of_IN recurrent_JJ stroke_NN has_VBZ been_VBN reported_VBN at_IN 13_CD %_NN to_TO 22_CD %_NN -LRB-_-LRB- with_IN one_CD recurrence_NN for_IN each_DT 24-41_CD patient-years_NNS -RRB-_-RRB- and_CC the_DT prevalence_NN of_IN TIA_NNP is_VBZ 19_CD %_NN ._.

In_IN particular_JJ ,_, the_DT Belgian_JJ experience_NN with_IN chronic_JJ transfusion_NN is_VBZ very_RB disappointing_JJ because_IN of_IN a_DT high_JJ rate_NN of_IN severe_JJ alloimmunization_NN ,_, mainly_RB explained_VBN by_IN the_DT absence_NN of_IN blood_NN donors_NNS of_IN African_JJ origin_NN ._. 

One_CD 18-year_JJ old_JJ patient_NN ,_, who_WP had_VBD received_VBN hydroxyurea_NN for_IN 11_CD months_NNS and_CC had_VBD only_RB a_DT slight_JJ reduction_NN in_IN the_DT frequency_NN of_IN painful_JJ episodes_NNS ,_, died_VBD suddenly_RB from_IN asystole_NN while_IN he_PRP was_VBD hospitalized_VBN for_IN a_DT painful_JJ crisis_NN ._. 

The_DT second_JJ one_CD occurred_VBD in_IN a_DT child_NN whose_WP$ past_JJ history_NN of_IN stroke_NN was_VBD not_RB the_DT reason_NN advocated_VBN by_IN his_PRP$ physician_NN for_IN hydroxyurea_NN treatment_NN ,_, this_DT reason_NN being_VBG the_DT existence_NN of_IN painful_JJ crises_NNS ._. 

Five_CD patients_NNS were_VBD splenectomized_VBN ,_, three_CD of_IN them_PRP have_VBP restarted_VBN hydroxyurea_NN with_IN good_JJ tolerance_NN ._. 

We_PRP ,_, therefore_RB ,_, recommend_VB careful_JJ evaluation_NN of_IN spleen_NN size_NN and_CC blood_NN tests_NNS at_IN each_DT evaluation_NN in_IN children_NNS with_IN previous_JJ splenomegaly_NN or_CC a_DT past_JJ history_NN of_IN splenic_JJ sequestration_NN before_IN starting_VBG hydroxyurea_NN ._. 

Respiratory_JJ failure_NN developed_VBN in_IN 46_CD percent_NN of_IN patients_NNS with_IN neurologic_JJ complications_NNS ;_: 92_CD percent_NN of_IN these_DT patients_NNS underwent_VBD transfusion_NN ,_, and_CC 23_CD percent_NN died_VBD ._. 

Chlamydia_NNP was_VBD the_DT most_RBS common_JJ isolate_VBP and_CC was_VBD associated_VBN with_IN an_DT increased_VBN rate_NN of_IN vaso-occlusive_JJ events_NNS ,_, although_IN the_DT rate_NN of_IN infection_NN with_IN this_DT organism_NN was_VBD similar_JJ to_TO that_DT in_IN the_DT general_JJ population_NN ._. 

Ex. 
Verdadeiro Positivo:
	episode_NN of_IN splenic_JJ sequestration_NN ._. 
	hypovolemic_JJ shock_NN from_IN splenic_JJ sequestration_NN ,_, 
	high_JJ rate_NN of_IN severe_JJ alloimmunization_NN ,_, 

Falso Positivo:
	episodes_NNS of_IN severe_JJ acute_JJ anemia_NN ._.